SLE nursing: assessment, management, and NCLEX review

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease in which the immune system loses tolerance to self-antigens and mounts an attack against the body’s own tissues. The result is widespread inflammation, immune complex deposition, and tissue damage spanning the skin, joints, kidneys, heart, lungs, blood, and central nervous system. SLE affects an estimated 1.5 million Americans, with global prevalence between 20 and 150 per 100,000 — and it remains one of the most clinically complex autoimmune conditions a nurse will encounter. Ninety percent of those affected are women, predominantly in their reproductive years, with significantly higher prevalence and severity in Black, Latina, and Asian women.

Understanding SLE’s immunologic mechanism, its protean clinical manifestations, and the nursing priorities that run across every body system is foundational to safe care — whether on a medical-surgical unit, in rheumatology clinic, or facing an NCLEX question that asks you to differentiate a malar rash from rosacea.

Quick reference: SLE at a glance

Pathophysiology

SLE is fundamentally a disease of failed self-tolerance and defective immune regulation. Under normal conditions, apoptotic cells (cells undergoing programmed death) are rapidly cleared by phagocytes before their nuclear contents can leak into surrounding tissue. In SLE, this clearance mechanism is impaired — nuclear material, including double-stranded DNA, histones, and ribonucleoproteins, persists in the extracellular space. The immune system, in a genetically susceptible individual, recognizes these nuclear antigens as foreign and mounts an antibody response against them: these are the antinuclear antibodies (ANA) that define the disease.

The most clinically important autoantibodies are:

• Anti-dsDNA (anti–double-stranded DNA): Highly specific for SLE; titers rise with disease activity and fall during remission, making them useful for flare monitoring
• Anti-Sm (anti-Smith): Highly specific for SLE (even more so than anti-dsDNA), but less sensitive (~25–30% of patients)
• Anti-Ro/SSA and anti-La/SSB: Important in neonatal lupus and Sjögren overlap
• Anti-phospholipid antibodies: Drive antiphospholipid syndrome (APS) — see dedicated section

These autoantibodies combine with their antigens to form immune complexes. The immune complexes circulate in the bloodstream and deposit in small vessel walls, glomeruli, synovium, choroid plexus, and skin — triggering the Type III hypersensitivity reaction that causes most of SLE’s organ damage. Complement proteins (C3, C4) are consumed as they attempt to clear the immune complexes; falling complement levels indicate active disease.

The downstream effects include:

• Glomerulonephritis (lupus nephritis) from immune complex deposition in the kidney
• Synovitis from immune complex deposition in joint capsules
• Serositis from inflammation of pericardial and pleural membranes
• Vasculitis and cutaneous inflammation from vessel wall deposition
• Cytopenias from autoantibodies targeting red blood cells, white blood cells, and platelets

Genetic susceptibility (HLA-DR2, HLA-DR3, complement deficiencies) and environmental triggers (ultraviolet light, infections, estrogens, certain medications) combine to initiate and perpetuate this cycle. The female predominance is at least partly attributable to estrogen’s amplifying effect on B-cell activity.

Clinical presentation and ACR/EULAR 2019 classification criteria

The 2019 ACR/EULAR classification criteria replaced the older 1997 ACR criteria with improved sensitivity and specificity. Classification requires a positive ANA (≥1:80 on Hep-2 cells) as the mandatory entry criterion, after which points are assigned across clinical and immunological domains. A score of ≥10 points classifies SLE.

The criteria organize SLE’s manifestations into seven clinical and three immunological domains:

Skin and mucous membranes

Malar (butterfly) rash — The classic SLE rash: flat or raised erythema across both cheeks and the nasal bridge in a butterfly distribution. Critically, it spares the nasolabial folds — this distinguishes it from rosacea, which involves the nasolabial folds. Triggered or worsened by sun exposure.

Discoid rash — Raised, scaly, erythematous plaques that heal with scarring and dyspigmentation, most commonly on the face, scalp, and ears. Unlike the malar rash, discoid lesions cause permanent hair loss and skin changes.

Photosensitivity — Exaggerated skin or systemic response to UV radiation. Even brief sun exposure can trigger a flare. Strict photoprotection is a cornerstone of SLE management.

Oral ulcers — Usually painless ulcers on the palate or buccal mucosa. Unlike aphthous ulcers (which are painful), lupus oral ulcers are often noticed incidentally during examination.

Non-scarring alopecia — Diffuse or patchy hair thinning without scalp scarring. Typically reversible with disease control, unlike scarring alopecia from discoid disease on the scalp.

Musculoskeletal

Arthralgias and symmetric non-erosive arthritis are present in up to 95% of SLE patients over the course of their disease. Unlike rheumatoid arthritis, SLE arthritis is non-erosive — it does not produce the bony destruction and joint space narrowing seen on X-ray in RA. Jaccoud’s arthropathy (reducible deformity from ligamentous laxity) can occur in advanced disease but without true erosions.

Morning stiffness may be present but is typically shorter than the >1-hour morning stiffness characteristic of RA. This is an important NCLEX differentiator.

Serositis

Pleuritis and pericarditis are common manifestations of serositis in SLE. Both result from immune complex deposition in the serosal lining. Pleuritis presents with pleuritic chest pain (sharp, worsened with inspiration) and may lead to pleural effusion. Pericarditis presents with sharp chest pain that improves when leaning forward; see the pericarditis nursing reference for complete assessment and management.

Renal

Lupus nephritis occurs in approximately 50% of SLE patients and is the leading cause of serious morbidity. All SLE patients should have urinalysis and urine protein measured at every clinical encounter. Proteinuria, hematuria, and red blood cell casts indicate active nephritis. Untreated, lupus nephritis progresses to CKD and ESRD.

Neuropsychiatric

Neuropsychiatric SLE (NPSLE) encompasses a broad spectrum: cognitive dysfunction (“lupus fog”), headache, seizures, cerebrovascular disease, transverse myelitis, peripheral neuropathy, and acute confusional state. Psychosis can occur and is difficult to distinguish from corticosteroid-induced psychiatric effects.

Hematologic

The ACR/EULAR criteria include three hematologic manifestations:

• Hemolytic anemia — autoantibodies against RBC surface antigens (Coombs-positive); contributes to fatigue and pallor. See the anemia nursing reference for hemolytic anemia assessment and management.
• Leukopenia/lymphopenia — lymphopenia (<1,000/µL) is particularly characteristic. Increases infection risk.
• Thrombocytopenia — autoantibodies against platelets; ranges from mild to severe. When below 50,000/µL, bleeding precautions apply — see the thrombocytopenia nursing reference for complete bleeding risk assessment.

Diagnostic evaluation

SLE is diagnosed based on clinical findings and serological testing in combination; no single test is sufficient. The diagnostic framework is summarized below.

SLE vs RA vs drug-induced lupus: key differentiators

Distinguishing SLE from rheumatoid arthritis and drug-induced lupus (DIL) is a frequently tested NCLEX topic. All three can present with arthritis, positive ANA, and systemic symptoms — but the pattern of organ involvement, serology, and clinical course differ significantly.

Pharmacological management

Hydroxychloroquine (Plaquenil) — the foundation of SLE therapy

Hydroxychloroquine (HCQ) is recommended for all SLE patients unless contraindicated. It is the single most important drug in SLE management — not because it suppresses acute flares as dramatically as steroids, but because long-term use reduces flare frequency, prevents organ damage (including lupus nephritis), reduces mortality, and has a proven safety record in pregnancy.

Mechanism: HCQ accumulates in lysosomes, alkalizes them, and disrupts antigen presentation by interfering with toll-like receptor signaling. This blunts the autoantibody-producing B-cell response.

Nursing considerations:

• Full effect takes 2–3 months — teach patients not to stop because they don’t notice immediate benefit
• Annual ophthalmology examination is mandatory for retinal toxicity screening (risk increases after 5 years of use or cumulative dose >5 mg/kg/day)
• Advise patients to report any new visual symptoms promptly
• Safe in pregnancy — should be continued throughout; discontinuation during pregnancy increases flare risk
• Smoking reduces HCQ efficacy — smoking cessation counseling is clinically relevant

NSAIDs

NSAIDs (ibuprofen, naproxen, celecoxib) are used for mild musculoskeletal symptoms, fever, and pleuritis/pericarditis pain in SLE. They do not modify disease course. Key nursing concerns: GI toxicity (consider PPI co-prescription), cardiovascular risk, renal effects (avoid or use with caution in lupus nephritis — NSAIDs impair renal prostaglandin-mediated blood flow), and fluid retention.

Corticosteroids

Corticosteroids (prednisone, methylprednisolone) are used for flare management and acute organ-threatening disease. Intravenous pulse methylprednisolone (1 g/day × 3 days) is used for severe renal or neuropsychiatric involvement. Long-term corticosteroid use carries substantial toxicities: hyperglycemia, hypertension, weight gain, osteoporosis, cataracts, adrenal suppression, and increased infection risk. The treatment goal is always to taper to the lowest effective dose.

Critical nursing instruction: Never abruptly discontinue corticosteroids after prolonged use — adrenal suppression requires a gradual taper.

Immunosuppressants

Biologics

Belimumab (Benlysta) was the first biologic approved specifically for SLE (2011, subcutaneous and IV formulations). It blocks B-lymphocyte stimulator (BLyS/BAFF), reducing B-cell survival and autoantibody production. Indicated for active, autoantibody-positive SLE despite standard therapy. Approved in 2020 for lupus nephritis induction.

Key nursing considerations for belimumab:

• Monitor for serious infections (immunosuppression)
• Screen for depression and suicidal ideation — belimumab carries an FDA warning for psychiatric adverse effects; assess mental health at baseline and at each visit
• No live vaccines during therapy
• IV infusion reactions possible — monitor vitals during infusion
• SC form: teach self-injection technique and site rotation

Anifrolumab (Saphnelo) — approved 2021 for moderate-to-severe SLE. Targets the type I interferon receptor (IFNAR1). An option when anti-dsDNA positive and elevated interferon signature. Not for lupus nephritis management alone.

Lupus nephritis

Lupus nephritis (LN) is the most serious and common organ-threatening complication of SLE, occurring in approximately 50% of patients. It results from immune complex deposition in the glomeruli, triggering complement activation, inflammatory cell recruitment, and progressive nephron loss.

ISN/WHO histological classification

The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification (replaces older WHO classification) defines six histological classes based on renal biopsy:

Monitoring lupus nephritis

All SLE patients require renal function monitoring at every clinical encounter:

• Urinalysis — proteinuria, hematuria, and RBC casts
• 24-hour urine protein (or protein-to-creatinine ratio)
• Serum BUN and creatinine/GFR
• Complement C3/C4 — low in active nephritis
• Anti-dsDNA titers — rising titer often precedes clinical nephritis flare

When GFR falls progressively or proteinuria exceeds 0.5 g/24h in SLE, urgent nephrology/rheumatology referral is required. Untreated progressive lupus nephritis leads to CKD and ESRD — 10–30% of lupus nephritis patients progress to end-stage renal disease within 10 years.

Antiphospholipid syndrome

Antiphospholipid syndrome (APS) is a hypercoagulable condition that occurs in 50–70% of SLE patients who test positive for antiphospholipid antibodies (APLA). It is the most common acquired thrombophilia. APS can occur in isolation (primary APS) or in the setting of SLE (secondary APS).

Diagnosis (Sapporo/Sydney 2006 criteria)

Requires one clinical criterion + one laboratory criterion, with laboratory findings confirmed on two separate occasions at least 12 weeks apart.

Clinical criteria:

• One or more episodes of arterial, venous, or small-vessel thrombosis
• Pregnancy morbidity: ≥3 consecutive unexplained miscarriages before 10 weeks, OR one fetal death at ≥10 weeks, OR premature birth before 34 weeks due to preeclampsia or placental insufficiency

Laboratory criteria (any one of):

• Lupus anticoagulant — functional clotting assay (prolonged PTT that does not correct with mixing study)
• Anticardiolipin antibodies IgG or IgM at medium-high titer (×2, ≥12 weeks apart)
• Anti-β2-glycoprotein-I antibodies IgG or IgM (×2, ≥12 weeks apart)

Clinical manifestations

• Venous thromboembolism — DVT is the most common presentation; PE is a major mortality risk. See the DVT nursing reference for complete thrombosis assessment.
• Arterial thrombosis — ischemic stroke is the most common arterial event; also TIA, MI, and peripheral arterial occlusion
• Recurrent pregnancy loss — second and third trimester losses; preeclampsia and HELLP syndrome
• Livedo reticularis — mottled, net-like skin discoloration
• Thrombocytopenia — mild-to-moderate, present in 15% of APS patients
• Cardiac valve abnormalities — Libman-Sacks endocarditis (sterile, non-bacterial thrombotic vegetations)
• Pulmonary hypertension — from recurrent pulmonary microthrombi; see pulmonary hypertension nursing
• Catastrophic APS (CAPS) — rare, life-threatening variant: multiple organ thrombosis within days; 50% mortality; requires anticoagulation + corticosteroids + plasma exchange/IVIG

Treatment

• Primary prevention (positive APLA, no thrombosis): low-dose aspirin (75–100 mg/day) in high-risk profiles; hydroxychloroquine in SLE patients
• Venous thrombosis: warfarin, target INR 2.0–3.0; lifelong in unprovoked events
• Arterial thrombosis: warfarin preferred over DOACs; INR 2.0–3.0 (some guidelines target 3.0 for arterial events)
• Pregnancy with APS: low-dose aspirin + prophylactic or therapeutic LMWH (heparin); warfarin is teratogenic and must be avoided in the first trimester and near delivery

Nursing alert: The lupus anticoagulant paradox is a classic exam trap. Lupus anticoagulant prolongs the PTT (and sometimes PT) in the laboratory because the antibody interferes with phospholipid-dependent clotting assays. In vivo, however, it causes thrombosis, not bleeding. A patient with lupus anticoagulant and a prolonged PTT does NOT have a bleeding disorder — they are at elevated thrombotic risk.

Pregnancy in SLE

SLE carries significant risks during pregnancy. Optimal outcomes require disease to be in remission for at least 6 months before conception, close multidisciplinary monitoring throughout, and careful medication management.

Maternal risks

• Lupus flares — especially during the postpartum period (estrogen surge)
• Preeclampsia — 3–4 times higher rate than the general obstetric population
• Preterm birth — common even in well-controlled disease
• Thrombosis (APS-driven)
• Fetal growth restriction

Fetal/neonatal risks

Neonatal lupus — caused by passive transfer of maternal anti-Ro/SSA and anti-La/SSB antibodies across the placenta. Manifestations include:

• Transient neonatal lupus rash (resolves within 6 months as maternal antibodies clear)
• Congenital heart block — the most serious neonatal complication. Maternal anti-Ro/SSA antibodies damage fetal AV node tissue. Can be complete (third-degree) heart block, which may require neonatal pacemaker implantation. Mothers with anti-Ro/SSA antibodies require fetal cardiac monitoring (echocardiogram) during the second trimester.

Medication safety in pregnancy

Nursing priorities and interventions

Photoprotection

UV radiation is the most potent environmental trigger for SLE flares. Every patient with SLE requires:

• Broad-spectrum sunscreen (SPF 50+ with UVA and UVB protection) applied daily to all exposed skin, regardless of weather
• UPF 50+ clothing, wide-brimmed hats
• Avoidance of peak UV hours (10 AM–4 PM)
• Note that window glass does not block UVA — sun exposure while driving or indoors near windows can trigger photosensitivity reactions

Infection prevention

Patients with SLE face a double infection risk: the disease itself causes immune dysregulation, and the immunosuppressant medications used to treat it further impair host defenses. Pneumonia, urinary tract infections, and opportunistic infections are leading causes of SLE-related hospitalization and mortality.

Nursing interventions:

• Monitor for early, subtle infection signs — fever may be blunted by corticosteroids and some biologics
• Markedly elevated CRP suggests infection rather than a lupus flare — escalate promptly
• Ensure vaccinations are up to date: pneumococcal, influenza, hepatitis B (especially before biologic initiation); no live vaccines during active immunosuppression
• Reinforce hand hygiene and avoidance of sick contacts
• Teach patients to contact their provider immediately for any fever over 100.4°F (38°C)

Medication adherence and education

Hydroxychloroquine adherence is the single most modifiable predictor of SLE outcomes. Non-adherence is associated with increased flare rates, organ damage, and mortality. Key education points:

• HCQ takes 2–3 months for full effect — do not stop because of perceived lack of response
• Eye exams: annual after 5 years of use; report any visual changes immediately
• Corticosteroids: never stop abruptly; take with food to reduce GI effects
• Immunosuppressants: adherence to monitoring labs is non-negotiable — labs detect toxicity before it becomes dangerous
• Contraception counseling for all reproductive-age women on teratogenic medications (methotrexate, mycophenolate)

Flare recognition

Teach patients to recognize warning signs of a lupus flare:

• Increasing joint pain or swelling
• New or worsening rash, especially after sun exposure
• Fever — even low-grade, distinguish from infection with provider input
• Increasing fatigue out of proportion to usual
• Changes in urine (foamy urine = proteinuria; pink/cola-colored = hematuria)
• New chest pain or shortness of breath (serositis)
• Headaches or cognitive changes (NPSLE)

Fatigue management

Fatigue is the most prevalent and debilitating symptom in SLE, affecting over 80% of patients. It results from chronic inflammation, anemia of chronic disease, corticosteroid-induced metabolic changes, poor sleep, depression, and disease activity.

Nursing interventions:

• Assess fatigue severity with a validated scale (FACIT-Fatigue) at each visit
• Identify treatable contributors: anemia (CBC), hypothyroidism (TSH), depression, sleep disorders
• Teach energy conservation techniques: activity pacing, prioritizing valued activities, scheduling rest periods
• Low-impact aerobic exercise (walking, swimming) reduces fatigue and improves quality of life — do not advise complete rest

Mental health support

Depression and anxiety affect up to 50% of SLE patients. Contributing factors include chronic pain, physical disability, medication side effects (particularly corticosteroids and belimumab), uncertainty about disease course, and — in young women — the impact on fertility, pregnancy, and body image from rashes and hair loss.

Nursing interventions:

• Screen for depression and anxiety at each encounter
• If belimumab is prescribed, document baseline psychiatric assessment and monitor at follow-up
• Refer to rheumatology social work, psychology, or patient support groups
• Validate the psychosocial burden — this is not a mild disease, and patients often feel their suffering is minimized

NCLEX tips

• Malar rash differentiator: The butterfly rash of SLE spares the nasolabial folds. Rosacea involves the nasolabial folds. Discoid lupus causes scarring; malar rash does not.

• ANA sensitivity vs. specificity: ANA is highly sensitive (>95%) but not specific for SLE. A positive ANA alone does not diagnose SLE. Anti-dsDNA and anti-Sm are specific; a negative ANA makes SLE unlikely.

• Anti-dsDNA tracks activity: In SLE, anti-dsDNA titers rise with disease activity and fall during remission. Low C3/C4 paired with rising anti-dsDNA = flare pattern.

• Lupus anticoagulant paradox: Lupus anticoagulant prolongs PTT in the lab but causes thrombosis in vivo — it does not cause bleeding. If you see prolonged PTT in an SLE patient, think thrombosis risk, not bleeding risk.

• Hydroxychloroquine is for all SLE patients: HCQ is recommended for every patient with SLE regardless of disease severity. It reduces flares, organ damage, and mortality. It is safe in pregnancy.

• CRP vs. ESR in SLE flares: In most inflammatory conditions, CRP rises prominently with disease activity. In SLE, CRP elevation is often modest during flares. A markedly elevated CRP should prompt evaluation for intercurrent infection.

• Lupus nephritis progression: Class III–IV (proliferative) lupus nephritis requires aggressive immunosuppression (MMF or cyclophosphamide + corticosteroids). Without treatment, it leads to CKD and ESRD. Urinalysis (proteinuria, hematuria, RBC casts) is the first-line screen.

• Drug-induced lupus vs. SLE: DIL is characterized by anti-histone antibodies, negative or absent anti-dsDNA, normal complement levels, and resolution of symptoms when the offending drug is stopped. Common causative drugs: hydralazine, procainamide, isoniazid.

• Neonatal heart block: Mothers with anti-Ro/SSA antibodies can transmit these antibodies across the placenta. The most serious consequence is congenital complete heart block in the fetus. Fetal cardiac monitoring (echocardiogram) is indicated during the second trimester for anti-Ro/SSA-positive mothers.

• Pregnancy and medication safety: Methotrexate and mycophenolate are contraindicated in pregnancy (teratogenic). Hydroxychloroquine is safe and should be continued. LMWH replaces warfarin for APS anticoagulation during pregnancy.

• Postpartum flare risk: SLE commonly flares in the postpartum period due to the hormonal shift after delivery. Patients require close monitoring in the weeks following birth.

• Infection risk priority: Immunosuppressed SLE patients are at high risk for serious infections. A patient presenting with fever should be evaluated for infection before attributing the fever to a lupus flare. This is a classic NCLEX prioritization scenario.

Related resources

The multisystem nature of SLE means nursing care extends across nearly every clinical domain. The following reference pages provide essential supporting knowledge:

• Rheumatoid arthritis nursing — Differentiating SLE arthritis (non-erosive, symmetric) from RA (erosive, symmetric, morning stiffness >1 hour), comparing serology, and understanding DMARDs used across both diseases
• Thrombocytopenia nursing reference — Immune thrombocytopenia in SLE: when to implement bleeding precautions, platelet transfusion thresholds, and monitoring
• Anemia nursing reference — Autoimmune hemolytic anemia in SLE: Coombs-positive hemolysis, distinguishing from anemia of chronic disease, and transfusion considerations
• Pleural effusion nursing — Lupus pleuritis and pleural effusion: assessment, drainage indications, and nursing care
• Pericarditis nursing — SLE serositis involving the pericardium: presentation, ECG findings, treatment, and tamponade recognition
• DVT nursing — Antiphospholipid syndrome-driven thrombosis: risk stratification, prophylaxis, anticoagulation management, and nursing care during warfarin/LMWH therapy
• CKD and ESRD nursing — Lupus nephritis progression to chronic kidney disease: staging, dietary management, dialysis considerations
• Pulmonary hypertension nursing — SLE-associated pulmonary arterial hypertension from APS microthrombi and immune complex–mediated pulmonary vascular disease